Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Zilovertamab Vedotin Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Merck Sharp & Dohme LLC	P2	B (57)
Zirconium Zr 89 Crefmirlimab Berdoxam Metastatic Malignant Solid Neoplasm	City of Hope Medical Center	P2	B (57)
Brentuximab Vedotin Child	Children's Cancer Group, China	P2/3	B (57)
Brentuximab Vedotin Metabolic Response	Children's Cancer Group, China	P2/3	B (57)
Brentuximab Vedotin PET Scan	Children's Cancer Group, China	P2/3	B (57)
Brentuximab Vedotin Young Adult	Children's Cancer Group, China	P2/3	B (57)
hlx43 Non-Small Cell Squamous Lung Carcinoma	Shanghai Henlius Biotech	P2/3	B (57)
Inotuzumab Ozogamicin Burkitt Lymphoma	SWOG Cancer Research Network	P1/2	B (57)
rc48-adc Double Blind	Sinocelltech Ltd.	P2/3	B (57)
T-Dxd Breast Neoplasms	Yan Xue	P4	B (56)
ABT-700-VCMMAE Non-Small Cell Lung Carcinoma	Jonsson Comprehensive Cancer Center	P3	B (56)
immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, conjugated at glutaminyl residues to monomethylauristatin E (MMAE), with a ratio of 1 to 2, via a cleavable linker HER2 Positive Breast Carcinoma	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P3	B (56)
Loncastuximab Tesirine Relapsed/Refractory Diffuse Large B-Cell Lymphoma	University of Utah	P3	B (56)
Puxitatug Samrotecan Endometrial Carcinoma	AstraZeneca	P3	B (56)
Sacituzumab Tirumotecan Cervical Cancer	Merck Sharp & Dohme LLC	P3	B (56)
Sacituzumab Tirumotecan Endometrial Carcinoma	Merck Sharp & Dohme LLC	P3	B (56)
Trastuzumab Deruxtecan Breast Neoplasm	Merck Sharp & Dohme LLC	P3	B (56)
Trastuzumab Deruxtecan Endometrial Carcinoma	AstraZeneca	P3	B (56)
ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166 Breast Cancer	Fudan University	P2	B (56)
Datopotamab Deruxtecan Triple-Negative Breast Carcinoma	UNC Lineberger Comprehensive Cancer Center	P2	B (56)
rc48-adc Melanoma	HiFiBiO Therapeutics	P2	B (56)
rc48-adc Pancreatic Neoplasm	Memorial Sloan Kettering Cancer Center	P2	B (56)
rc48-adc Solid Tumor	InxMed (Shanghai) Co., Ltd.	P2	B (56)
rc48-adc Triple Negative Breast Cancer	Seagen, a wholly owned subsidiary of Pfizer	P2	B (56)
ds-8201a Breast Cancer	MedSIR	P2	CCC (55)

Showing 226 to 250 of 1,027 assets

PreviousPage 10 of 42Next